Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 5, 2026

Stock market today: Dow falls more than 1,000 points, S&P 500 and Nasdaq tank as Iran war jitters return with another oil surge

View original at finance.yahoo.com
Stock market today: Dow falls more than 1,000 points, S&P 500 and Nasdaq tank as Iran war jitters return with another oil surge US stock losses accelerated on Thursday as Wall Street failed to build on a rebound session, with conflict in the Middle East holding focus amid a renewed surge in oil prices…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Block seeing 40% increase in engineering productivity since September

    80% confidence
  • Fed continuing easing would risk that a 30-50bp inflation overshoot gets entrenched

    80% confidence
  • US doing very well on the war front

    80% confidence
  • Tariffs contributed roughly 50 basis points to core PCE inflation, but that's only half the Fed's inflation problem

    80% confidence
  • Absolutely believes in Berkshire and inherited company with incredible foundation

    80% confidence
  • US will offer risk insurance and naval escorts for ships transiting Strait of Hormuz

    80% confidence
  • Goal was to demonstrate alignment with shareholders as CEO

    80% confidence
  • American forces moving toward complete and total control of Iranian airspace

    80% confidence
  • Will use all take-home pay to keep buying Berkshire stock

    80% confidence
  • Nvidia has not yet generated any revenue from H200 chips for China

    80% confidence
  • Strait of Hormuz remains open but increasingly threatened tankers attempting to cross

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com